Fresenius has closed the buyout of the minority stake in mAbxience, turning a four-year majority partnership into a fully owned biosimilars and biologics manufacturing platform inside Fresenius Kabi. For hospital buyers, payers, and rival CDMO and biosimilar developers, the move is less about a fresh entry and more about who controls capacity, launch timing, and economics as biologic exclusivity cliffs approach.
What happened
Fresenius SE & Co. KGaA announced that it has acquired the remaining 45% of mAbxience Holding S.L. from Insud Pharma S.L. and Invim Corporativo, S.L. for total consideration of up to EUR 750 million, including a EUR 50 million contingent payment tied to site approvals. The deal was signed and completed on 30 September 2026, with no regulatory clearances required.
Fresenius first took a 55% stake in August 2022 and has controlled and consolidated mAbxience since then. Full ownership folds the Spanish-based developer and manufacturer wholly into Fresenius Kabi Biopharma under one economic owner. Jurgen Van Broeck remains chief executive of mAbxience and will report to Dr. Sang-Jin Pak, President Biopharma at Fresenius.
mAbxience operates three multi-product drug-substance facilities in Spain and Latin America and employs more than 1,300 people. In 2025 it generated more than EUR 320 million in revenue, with an EBITDA margin Fresenius said was accretive to the broader Fresenius Kabi margin. The book includes four marketed products and eight candidates in development, plus contract manufacturing for partners across a B2B network Fresenius describes as active in more than 100 markets.
Funding comes from available liquidity and operating cash flow; no new financing was raised. Fresenius expects net debt to EBITDA to rise by about 20 basis points, with full-year leverage still toward the lower end of its 2.5x to 3.0x target corridor. Under IFRS, buying the non-controlling interest is an equity transaction, so no goodwill is created. Management says the deal is immediately accretive to Group core earnings per share and leaves full-year 2026 guidance unchanged, along with the longer 2030 Biopharma ambition.
Why it matters
Majority control already gave Fresenius consolidation and operational influence. Buying the remaining 45% changes the capital allocation story: every incremental euro of biosimilar profit, CDMO margin, and pipeline optionality now sits with Fresenius shareholders rather than minority sellers. That matters when biologics lose exclusivity in clustered waves and when manufacturing slots, tech-transfer timelines, and partner economics decide who can supply hospital formularies at scale.
The structure also removes put-option overhang on the balance sheet. Settling the recognized liability for the 45% stake cleans a contingent claim and clarifies the Biopharma perimeter inside the FutureFresenius playbook. For a BBB-rated group still prioritizing deleveraging, paying cash from free cash flow for a business it already knows is a different risk profile from a greenfield platform buy.
Strategically, full ownership tightens the link between Fresenius Kabi commercial reach and mAbxience manufacturing. Buyers of sterile injectables and biosimilar monoclonal antibodies care about dual sourcing, inspection history, and launch certainty. A single owner can prioritize capacity expansions, site-approval contingencies, and partner licenses without negotiating minority consent each time. Teams tracking Healthcare & Medical Devices supply chains will read this as vertical integration hardening, not a bolt-on brand purchase.
Who feels it
Hospital pharmacy and group purchasing organizations gain a clearer counterparty for Fresenius Kabi biosimilar and CDMO capacity, but also a more concentrated supplier on certain molecules if rival plants do not expand in parallel. Rival biosimilar developers and pure-play CDMOs face a better-funded competitor that no longer splits economics with minority owners.
Insud Pharma and Invim Corporativo exit a successful partnership after roughly a decade of building mAbxience, crystallizing value as Fresenius chooses to own rather than partner. Employees across the three plants sit under a single strategic umbrella, which can mean faster capex decisions and tighter quality systems, but also integration pressure on culture and incentives that grew under a more entrepreneurial ownership mix.
Payers and tender authorities in Europe and Latin America should watch whether full ownership translates into more aggressive tender participation or steadier supply commitments. Licensing partners that rely on mAbxience for drug substance will care most about continuity of quality agreements and whether Fresenius redirects capacity toward its own pipeline first.
What to watch
First, track the EUR 50 million contingent tranche and any public updates on site approvals that unlock it; that is the near-term operational milestone baked into the price. Second, watch how Fresenius sequences the eight pipeline candidates versus CDMO slots for third parties when demand spikes around loss-of-exclusivity windows. Third, monitor leverage versus the 2.5x to 3.0x corridor and whether Biopharma investment stays inside the unchanged financial framework management described at close.
Competitive responses matter too: expect other hospital-focused generics and biosimilar groups to revisit minority stakes and joint ventures that leave strategic capacity half-owned. For deeper category context on devices, diagnostics, and adjacent care models next to injectable biologics in hospital budgets, see our Healthcare & Medical Devices coverage. Official transaction terms are on the Fresenius acquisition page for mAbxience, which buyers and rivals should keep bookmarked as integration milestones appear.
Bottom line: Fresenius did not discover biosimilars in September 2026; it finished buying the factory floor it already ran. The question for the next four quarters is whether full economic ownership shows up as faster launches, thicker CDMO books, or simply cleaner accounting around a platform the group already consolidated.